Objective We retrospectively analyzed the midterm clinical and angiographic outcomes after the implantation of paclitaxel-(PES, TAXUS Express) and sirolimus-(SES, Cypher Bx Velocity) eluting stents in Japanese patients with complex coronary lesions. Methods From August 2004 to May 2009, 1,335 nonrandomized de novo native complex coronary lesions treated with either a PES (357 cases) or SES were included. The inclusion criteria for patients with complex lesions were those with diabetes, those undergoing hemodialysis, and those with a low ejection fraction, as well as subjects who had lesions with severe calcification, ostiums of the right coronary and left circumflex arteries, and who underwent the side-branch bifurcation 2-stent technique. The subjects were evaluated for consistent predictors of cardiac events, binary restenosis and target lesion vascularization of the SES. The composite primary endpoint percentage (900-day cardiac death, nonfatal recurrent myocardial infarction, and definite stent thrombosis) after PES placement was 0.6%, which was not significantly different from that after SES placement (0.12%; p=0.290). The incidence of the secondary endpoint (binary restenosis; stenosis > 50% of the diameter at the secondary angiographic examination performed within 550 days after the procedure) after PES placement (15.0%) was also not significantly different than that after SES placement (13.3%; p=0.498). There was no relationship between PES placement and binary restenosis upon angiographic followup of 989 lesions (odds ratio of 1.14; 95% confidence interval, 0.73-1.77; p=0.57). Conclusion For de novo native complex coronary stenosis, the midterm safety and efficacy of PES placement was statistically equivalent to that of SES placement in a clinical setting in Japan.
Introduction
The paclitaxel-eluting stent (PES) (TAXUS Express; Boston Scientific, Natick, MA, USA) was the second coronary drug-eluting stent (DES) to be approved after the sirolimuseluting stent (SES) (Cypher Bx Velocity; Cordis Corp., Miami, FL, USA) in Japan. Previous studies have compared stents, without increasing the mid-term adverse cardiac events, including stent thrombosis (ST), in Japan (3). However, following the widespread application of percutaneous coronary intervention (PCI), novel problems have been raised about using DES for complex lesions in patients considered to have predictors of severe cardiac events, binary restenosis, and TLR of SES, such as diabetes, hemodialysis, and a low ejection fraction (EF), as well as those with lesions with severe calcification, ostiums of the right coronary and left circumflex arteries, and who have undergone the side-branch bifurcation 2-stent technique (3) (4) (5) . Therefore, in order to improve the rate of complete coronary revascularization by combining the advantages of DESs, it was necessary to examine the impact of the novel DES approved after SES, PES, on those complex lesions.
Therefore, the present study examined the midterm clinical and angiographic outcomes of PES versus SES in Japanese patients with complex coronary lesions, comprising those with consistent predictors of severe cardiac events, binary restenosis, and TLR (3) (4) (5) . We retrospectively analyzed the 900-day clinical and 550-day angiographic outcomes after PES and SES implantations in patients with complex coronary lesions.
Materials and Methods

Study design and population
The present study was a nonrandomized, single-center (Saitama Cardiovascular and Respiratory Center), lesionbased, retrospective study conducted in December 2011. The inclusion criteria were patients with de novo stenosis in native coronary arteries that were successfully and exclusively treated by elective PES or SES and who had not undergone a prior coronary artery bypass graft (CABG). Treatment was considered successful based on the absence of periprocedural complications [i.e., death, Q-wave myocardial infarction (MI), and emergency CABG]. Furthermore, patients were enrolled when post-procedural antegrade coronary flow determined thrombolysis in myocardial infarction (TIMI) grade 3 flow with acceptable stent expansion, as determined by angiography and IVUS. Complex lesions were defined based on previous data identifying the predictors of binary restenosis as TLR, a severe cardiac event after SES treatment (3) (4) (5) , patients with diabetes, hemodialysis, and a low EF, and lesions with severe calcification, ostiums of the right coronary and left circumflex arteries, and previous use of the side-branch bifurcation 2-stent technique. In addition, patients who had lesions with a post-procedural lumen diameter >1.35 mm, stenosis of <40% of the diameter, and a reference diameter ! 3.75 mm were included. The cases who underwent PCI supported by intra-aortic balloon pumping were excluded.
From 
Procedures for stenting and antiplatelet therapy
All patients were informed of the necessity of PCI and stenting, and informed consent was obtained. The device used to successfully treat the lesion by stenting was subject to the doctor's discretion. During the procedure, heparin (5,000-8,000 IU) was administered. The stents were implanted by visual angiographic estimation to cover the entire baseline lesion under the guidance of intravascular ultrasonography (IVUS-guide) ( Table 1) . When further stent dilation was needed, high-pressure ballooning with a noncompliant balloon (6) was typically performed. Rotational atherectomy with a rotablator was used (i) when it was impossible to insert the devices (a small-sized balloon and/or IVUS device) and (ii) when the balloon used for pre-dilation of the target lesion was indented (7) .
Periprocedural antiplatelet therapy was conducted as previously reported (3, 4) . When elective PCI was planned, aspirin (81-100 mg) and ticlopidine (200 mg) were orally administered approximately 10 days before the index procedure. After the procedure, ticlopidine (200 mg/day) was prescribed for a minimum of 12 months, although these prescriptions were not prospectively randomized. Cilostazol (200-300 mg/day) or clopidogrel (75 mg/day) was administered at the doctor's discretion if the patient had any adverse reactions to ticlopidine. From November 2007 to March 2008, clopidogrel was the first-line thienopyridine agent.
Follow-up angiogram and quantitative coronary artery (QCA) evaluation
The angiographic outcomes at the follow-up angiogram (fu CAG) through December 2011 were included in the analyses. The fu CAG was planned approximately 8-18 months (within 550 days) after the procedure. The rate of fu CAG was 70.3% (257 among 357 cases) in the PES group and 76.6% in the SES (749 among 978 cases) group (no significant difference; p=0.084). The QCA parameters were measured using a TCS cardiovascular network system (CAAS-2 and CAAS-5 system, Netherlands), as described previously (3, 4, 8) . Values were obtained at three time points: before PCI (pre-procedural), immediately after successful PCI (post-procedural), and during the chronic phase (follow-up). The measurements included the minimal lumen diameter (MLD), % diameter stenosis (% DS), and reference diameter (RD). In cases showing occlusions at the preprocedure and follow-up stages, the MLD was considered 0, and the %DS was considered 100. Additionally, we calculated the acute gain (post-procedural MLD minus pre- 26 baseline variables related to patients, lesions, and procedures and 5 variables related to the primary endpoint are shown. The definitions of the variables are as follows: age (age at stenting); male gender; diabetes (patients with diabetes mellitus); low EF (ejection fraction of left ventricle less than 40 as evaluated by ultrasonography or left ventriculogram); location of the culprit lesion in the left anterior descending artery (LAD) and right coronary artery (RCA); calcification (moderate to severe calcified lesions estimated using an angiogram and IVUS); ostial lesions of left circimflex artery (LCX ostium) and RCA (RCA ostium); bifurcation (bifurcative lesions requiring treatment of the side branch); CTO (chronic total occlusion more than 3 months); side-branch stenting (side branch of bifurcation 2-stent technique); IVUS (availability of IVUS during PCI); number of stents (number of implanted stents per lesion); diameter of balloon (maximum diameter of the balloon used to dilate the stent); length of stent (length of the stented segment calculated by adding the lengths of each stent regardless of overlap); pressure (maximum pressure at the maximum diameter of the inflated balloon); clinical observational interval (duration in days monitored after the index procedure). The lesion location, calcification, bifurcation, ostial lesion, and CTO variables were defined according to the American College of Cardiology and/or American Heart Association classification of lesions. Before PCI (pre-procedural) and immediately after successful PCI (post-procedural), the minimal lumen diameter (MLD), % diameter stenosis (DS), and reference diameter (RD) were assessed. Additionally, we calculated acute gain (post-procedural MLD minus pre-procedural MLD). The definition of the primary endpoint is provided in the text. procedural MLD) and late luminal loss (post-procedural MLD minus MLD at the chronic phase). Binary restenosis was defined as a % DS >50 at the fu CAG. Severe stenosis (% DS ! 70 at follow-up), typically treated as clinical TLR, was also assessed. The incidence of TLR after the fu CAG was assessed mainly by visual estimation of angiographic outcomes.
Endpoints and baseline variables of the enrolled patients
The safety (primary) endpoint of the clinical outcome was the cardiac-event composite comprising target vessel-related death without a definite non-cardiac cause (cardiac death), nonfatal re-MI, and definite (early, late, and very late) ST, as defined by the ARC (9), within 900 days after the index procedure. The efficacy (secondary) endpoint of the angiographic outcome was defined as the incidence of binary restenosis within 550 days after the index procedure.
Statistical analyses
The baseline characteristics are expressed as the means ± standard deviation (SD). The PES and SES group variables (both at baseline and at angiographic follow-up) were compared using unpaired t-tests for continuous values and χ 2 tests for categorical values. The present study compared the safety and efficacy between SES and PES. Therefore, the (Table 3 ). The predictors of binary restenosis were analyzed using a logistic regression analysis by including 12 variables (hemodialysis, LAD, RCA ostium, LCx ostium, CTO, side-branch stenting, PES, number of stents, length of stent(s), pre-procedural MLD, pre-procedural %DS, and acute gain) ( Table 1 shows the baseline characteristics and primary endpoints of the PES (n=357) and SES (n=978) groups. Among the patients, lesions, and procedural characteristics, the percentage of RCA (32.8%), bifurcation (43.4%), and mean pressure (18.1±3.03 atm) in the PES group were significantly different than those in the SES group (26.9%, 52.5%, and 19.9±3.13 atm, respectively) (p<0.05, <0.01, and <0.001, respectively).
Results
Baseline characteristics and primary endpoints
The lesion-based incidence of the primary endpoint in the PES group (0.6%; mean follow-up of 873±133 days) was not significantly different from that in the SES group (0.12%, p=0.447; mean follow-up of 879±112 days). 
Baseline characteristics of lesions with and without a primary endpoint
Predictors of the primary endpoint
Effects of baseline characteristics on angiographic follow-up lesions and angiographic outcomes
The baseline characteristics of 989 lesions with angiographic follow-up and the angiographic outcomes with secondary endpoints in the PES group (n=246) and SES group (n=743) are shown in Table 4 . The incidence of bifurcation (45.6%) in the PES group was significantly lower than in the SES group (54.4%; p<0.05). The mean pressure (18.0± 3.06 atm), follow-up MLD (2.01±0.67 mm), and late luminal loss (0.48±0.68 mm) in the PES group were significantly different from those in the SES group (19.8±3.12 atm, 2.17±0.72 mm, and 0.32±0.68 mm, respectively) (p< 0.001, <0.01, and <0.001, respectively).
The incidence of binary restenosis in the PES group (15.0%) did not significantly differ from that in the SES group (13.3%; p=0.498). The incidence of severe restenosis in the PES group (4.1%) was also not significantly different from that in the SES group (5.0%; p=0.559), nor was the incidence of TLR in the PES group (12.6%) significantly different from that in the SES group (12.0%; p=0.795). Table 5 shows the baseline characteristics of lesions with the secondary endpoint (binary restenosis group) (n=136) and without the secondary endpoint (no binary restenosis 29 baseline variables related to patients, lesions, and procedures and 4 variables related to the secondary endpoint are shown. The definitions of the variables are described in Table 1 and as follows: interval for angiographic follow-up (duration in days after the index procedure). Before PCI (pre-procedural), immediately after successful PCI (post-procedural), and at the chronic phase (follow-up), the minimal lumen diameter (MLD), % diameter stenosis (DS), and reference diameter (RD) were assessed. Lesion length (LL) was obtained at 2 points (preprocedure and at follow-up). Additionally, we calculated acute gain and late luminal loss (post-procedural MLD minus MLD at chronic phase). Binary in-stent restenosis (binary restenosis) was defined as % DS > 50 at fu CAG. Severe stenosis (% DS ≥ 70 at follow-up), typically treated as clinical target lesion revascularization (TLR), was also compared. TLR was evaluated mainly by visual estimation of angiographic outcomes. Tables 1 & 4. group) (n=853). 
Baseline characteristics of lesions with and without binary restenosis
PES
Predictors of binary restenosis in 989 angiographic lesions
The results of a logistic regression analysis performed to identify the predictors of binary restenosis after treatment with PES or SES are shown in Table 6 . The multivariate analysis identified the following predictors as being significant: hemodialysis [odds ratio (OR), 4.34; 95% CI: 1.91- 
Discussion
This retrospective, nonrandomized, single-center study assessed the mid-term (mean follow-up interval of approximately 2.3 years) safety and efficacy of PES (TAXUS Express) for the treatment of complex lesions in Japan. The present study was undertaken because there have so far been only a few studies in Japan investigating the outcomes of using first generation DES by comparing the safety and efficacy of PES versus SES (1, 2) . The present study was the first investigation of the impact of PES on complex lesions in patients with conventional predictors of SES failure. Our results demonstrated favorable midterm safety of the PES without definite ST for patients with various predictors commonly reported in Japan (binary restenosis, TLR, and severe cardiac events) (3-5, 10, 11) (Table 1, 2): more than 75% of the lesions were in patients with diabetes (12); approximately 20% of the lesions displayed calcification (4, 13, 14) , >10% were ostial (4, 15) , diffuse lesions treated with long stents (mean length of stent more than 35 mm) (15, 16) , and >10% used the bifurcation 2-stent technique (3, 4, 10, 15) . Among the present cohort, hemodialysis, a low EF, IVUS and age were the significant predictors of severe cardiac events (Table 3) , which was consistent with the findings of previous reports (3, 5, 10, 17) .
However, over a mean follow-up period of 2.3-2.4 years, the percentages of severe cardiac events after PES or SES placement (within a few percentages) were acceptable and more favorable compared to those in Western countries (18) (19) (20) (Table 1) . Specifically, the rate of severe cardiac events in Western studies was approximately 7.5-14.5% after one year, and not only were some of the predictors analyzed in the present study not included in those studies, but the percentages of patients with variables such as diabetes, calcification, ostial lesions, and use of the bifurcation 2-stent technique were much higher in our study than in those studies (18) (19) (20) . Accordingly, we herein provided the first demonstration of the mid-term safety of PES for the treatment of complex lesions with predictors of cardiac events, binary restenosis, and TLR in Japanese patients by evaluating 1,335 de novo native complex coronary stenosis lesions in a total of 840 patients.
The present nonrandomized study shows that PES and SES are statistically equivalent in terms of their efficacy with regard to the incidences of binary restenosis and TLR within 550 days (Table 4) . Almost all of the variables were statistically equivalent between the groups at baseline in the angiographic follow up of all 989 lesions (Table 4) , and the use of PES was not related to predictors of binary restenosis ( Table 6 ). The mean late luminal loss after PES placement was 1.5-fold higher than that after SES placement. However, the overall binary restenosis ratio after PES placement for de novo native complex coronary lesions was statistically equivalent (a 12.8% increase) to that after SES placement (Table 4) . Therefore, despite less late luminal loss after SES placement, the use of SES was not more advantageous than the use of PES (e.g., it did not have a more potent antirestenotic effect by reducing the growth of intima), since the binary restenosis ratio was equivalent to that of PES. This finding is consistent with a previous report (21) . Therefore, our nonrandomized study demonstrates that the midterm safety and efficacy of PES and SES are statistically equivalent based on the 900-day clinical and 550-day angiographic outcomes among a selected complex cohort (Table 2, 4). Since PES increase the long-term patency (no increase in late loss from 6 months to 2 years after placement) (22) compared to SES (23), a long-term follow-up is needed to compare the angiographic efficacy between PES and SES. In addition, the present study showed the necessity of performing further investigations to examine the impact of the present second generation DESs on the failures of the first generation DESs (SES and PES) in order to raise the rate of complete revascularization.
The present study had several limitations that should be kept in mind when interpreting the results of the study. First, we utilized a retrospective, non-randomized, and single-center analysis. Since the duration of SES treatment was longer than that of PES, there was a large difference in the cohort numbers between the PES and SES groups. The present cohort had lower fewer patients on hemodialysis, predictors of cardiac events, and binary restenoses after the implantation than did a Japanese previous study (10) . The lower rate of fu CAG among the PES group might also have underestimated the efficacy of PES (Table 2) . Furthermore, the duration of dual antiplatelet therapy and the choice of thienopyridine agent (ticlopidine or clopidogrel) depended on the doctor's judgment. The number of patients who were noncompliant with or discontinued dual antiplatelet therapy due to surgical and bleeding complications was also not fully examined. However, there was no increase in the number of cardiac events or definite ST events (Table 1) . Finally, other predictors of cardiac events, such as medications, renal dysfunction, and anemia were not examined.
Conclusion
This retrospective, nonrandomized study showed that, over a mean interval of 2.3-2.4 years, the midterm clinical and angiographic outcomes of PES placement for selected de novo native complex coronary lesions in Japanese patients were acceptable and statistically equivalent to those of SES placement.
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